- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07834242
Anaesthesia for Hip and Knee Arthroplasty (SPIGA) (SPIGA)
Spinal Versus General Anaesthesia for Hip and Knee Arthroplasty. The Randomised, Clinical, Multicentre SPIGA Trial
Beneficial and harmful effects of spinal versus general anaesthesia in patients undergoing hip and knee arthroplasty.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Effective and safe anaesthesia is fundamental to perioperative care. Hip and knee arthroplasty are among the most frequently performed surgical procedures worldwide and are typically performed under either spinal or general anaesthesia. However, high-quality comparative evidence regarding the benefits and harms of these anaesthetic techniques remains limited and inconclusive.
Both techniques are associated with short- and long-term risks, including postoperative nausea and vomiting, hypotension, nerve injury, acute kidney injury, and respiratory and cardiovascular complications. In addition, they may differentially modulate the surgical stress response, potentially influencing postoperative recovery and risk of complications.
Objective:
To compare the benefits and harms of spinal versus general anaesthesia in patients undergoing hip or knee replacement. We hypothesise that spinal anaesthesia results in better postoperative outcomes than general anaesthesia.
Intervention:
Patients undergoing elective primary hip or knee arthroplasty will be randomised to receive either spinal or general anaesthesia, with randomisation stratified by participating centre.
Design:
The SPIGA trial is an investigator-initiated, multicentre, randomised, superiority clinical trial. Participants will be randomly allocated at a 1:1 ratio using a central, computer-generated randomisation sequence. A total sample size of 3000 participants was determined using simulation-based methods to provide at least 90% power to detect a prespecified minimally clinically important difference, corresponding to an increase of one hospital-free day in at least 10% of participants at a two-sided significance level of 0.05.
Planned sub-studies
- Short-term perioperative outcomes (0-24h postoperatively)
- Stratified analysis of anaesthetic regimens
- Impact of preoperative clinical frailty
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled for elective primary elective hip or knee arthroplasty, including unicompartmental knee
Exclusion Criteria:
- Scheduled for elective primary hip or knee arthroplasty, including unicompartmental knee
- Age ≥ 18 years
- Unable to communicate in written and/or spoken Danish Contraindications against either spinal or general anaesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Spinal Anaesthesia
|
Spinal anaesthesia according to local practice, including optional sedation with sedative-hypnotic pharmacological agents |
|
Active Comparator: General Anaesthesia
|
General anaesthesia according to local practice |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospital-free days within 30 days
Time Frame: Postoperative day 0-30
|
Defined as the number of days within the first 30 days following hip or knee arthroplasty surgery during which a participant is alive and not admitted to a hospital. |
Postoperative day 0-30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major complications
Time Frame: Postoperative day 0-30
|
A major complication is defined as a major intra- or postoperative adverse event occurring from the initiation of anaesthesia through 30 days postoperatively. |
Postoperative day 0-30
|
|
Quality of Recovery
Time Frame: 24 hours postoperatively
|
The Quality of Recovery-15 questionnaire (QoR-15) generates a composite score ranging from 0 to 150 across five domains (physical comfort, emotional state, physical independence, psychological support, and pain), with higher scores indicating better recovery. |
24 hours postoperatively
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction with anaesthesia
Time Frame: 24 hours postoperatively
|
Assessed 24 hours postoperatively by asking patients to rate their satisfaction on a numeric rating scale (NRS) from 0-10, where 0 indicates not satisfied at all/completely dissatisfied and 10 indicates extremely satisfied/fully satisfied. |
24 hours postoperatively
|
|
Health-related quality of life (EQ5D5L-VAS)
Time Frame: Postoperative day 30
|
Evaluation of health-related quality of life using the EuroQol EQ5D5L- VAS questionnaire that adresses mobility, self-care, usual activities, pain/discomfort, anxiety/depression. The VAS is a vertical visual analogue score of self-rated health (EQ-VAS, 0 = "The worst health you can imagine" and 100 = "The best health you can imagine"). |
Postoperative day 30
|
|
Number of unplanned hospital-visits
Time Frame: Postoperative day 0-30
|
Defined as the number of any unplanned contact with the emergency department, outpatient clinic, or other hospital department. |
Postoperative day 0-30
|
|
Willingness to repeat the type of anaesthesia
Time Frame: 24 hours postoperatively
|
Assessed at 24 hours postoperatively by asking participants whether they would choose the same type of anaesthesia again in case of future surgery. |
24 hours postoperatively
|
|
Day-case discharge
Time Frame: Postoperative day 0
|
Number of patients assessed as eligible for day-case surgery being discharged on the day of surgery. |
Postoperative day 0
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMN-2026-05830
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Data will be published anonymised in accordance with ICMJE (International Committee of Medical Journal Editors) guidelines.
IPD Sharing Time Frame
The study protocol and statistical analysis plan will be available after they have been published.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.